Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting.
about
The ER-resident ubiquitin-specific protease 19 participates in the UPR and rescues ERAD substratesThe Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase ItchHomozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS11)Nedd4 augments the adaptive immune response by promoting ubiquitin-mediated degradation of Cbl-b in activated T cellsRare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophyThe ubiquitin proteasomal system: a potential target for the management of Alzheimer's diseaseThe protein quality control machinery regulates its misassembled proteasome subunitsAntigen processing via autophagy--not only for MHC class II presentation anymore?Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignanciesSuppression of the ligand-mediated down-regulation of epidermal growth factor receptor by Ymer, a novel tyrosine-phosphorylated and ubiquitinated proteinDystonia-associated mutations cause premature degradation of torsinA protein and cell-type-specific mislocalization to the nuclear envelopeMatrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes.Validation of microarray data in human lymphoblasts shows a role of the ubiquitin-proteasome system and NF-kB in the pathogenesis of Down syndrome.Different degree in proteasome malfunction has various effects on root growth possibly through preventing cell division and promoting autophagic vacuolizationPhase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.Scaffold protein FHL2 facilitates MDM2-mediated degradation of IER3 to regulate proliferation of cervical cancer cells.Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamidesUbiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implicationsAcetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth.The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy.Parkin-mediated K63-polyubiquitination targets ubiquitin C-terminal hydrolase L1 for degradation by the autophagy-lysosome system.Dual proteolytic pathways govern glycolysis and immune competence.Defining the transcriptome and proteome in three functionally different human cell lines.Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cellsThe cyclophilin-like domain of Ran-binding protein-2 modulates selectively the activity of the ubiquitin-proteasome system and protein biogenesis.Regulation of ASIC activity by ASIC4--new insights into ASIC channel function revealed by a yeast two-hybrid assay.Drosophila morgue associates with SkpA and polyubiquitin in vivoDynamics of the degradation of ubiquitinated proteins by proteasomes and autophagy: association with sequestosome 1/p62.The dynamic nature of autophagy in cancerSimultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cellsDevelopment of withaferin A analogs as probes of angiogenesisDisruption of a mitochondrial protease machinery in Plasmodium falciparum is an intrinsic signal for parasite cell death.Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularizationLysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy.Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.iRhom1 regulates proteasome activity via PAC1/2 under ER stressThe ubiquitin-proteasome system meets angiogenesis.Aggregate reactivation mediated by the Hsp100 chaperonesCholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1 -/- mouse brainDrug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
P2860
Q24313484-5D81986F-906F-4DD2-87C3-86F3D4AA0DFCQ24314498-B6012F47-4CEC-4A1B-BB50-FB270D705C92Q24546392-4A407E1C-AC95-4ECF-9722-D03E8D29D325Q24615775-524935CC-29EC-4019-BA03-705230661E9CQ24643967-05C76558-0250-4DA7-B116-A70E7ED843DCQ26749321-E4CBCE3E-797E-4DE7-9C15-F6C4C270BFC6Q27311236-D591C184-FB22-442D-B306-41CD7130D3D3Q27687223-AA0EC84D-69BF-4EAC-8826-C6ECF31E4959Q28072922-CCB38334-D46B-4401-BD8A-05E403C89436Q28248770-15667993-FCE5-49FF-B115-F0415A7C1BE7Q28386148-563061C2-507B-44FB-9B5A-A6B5B213A1A7Q30491528-EB51BE23-48F6-4B62-9793-A9147615BCDBQ30653697-86F1A1D2-B28E-4615-96EB-A8EE664645E2Q33354457-3B7DD315-4BDD-4908-B890-9A56001A8989Q33427510-D79FCBAF-2B85-4287-A1CA-9663E535F2EFQ33586638-26A229B1-E13A-46A2-ADEF-41737428F26DQ33836952-C3D570F7-C339-48FD-90D6-DB947B45E499Q34012297-7BD202FA-EE3A-4140-BD21-C8EB2ECFDFE0Q34195003-74CDEBE2-28F6-4312-9365-A1C5CF07232BQ34202686-E5218AB7-CB71-4906-A383-344B046EFA98Q34448273-8ACB265B-A09E-4217-94A5-6235A057083BQ34454822-49D1F809-6786-441D-B4C8-8F6DEE644B76Q34476804-C14E9180-C10B-4F53-88D9-917819D66DC0Q34656908-F6064DA1-69EA-4987-96D8-60F78A859171Q34696926-2D41EC00-C5BE-463C-BED5-602706A5B168Q34801941-C1D2DE90-F9B1-4A3F-8755-E3C9350A3F30Q35009919-72E0B869-55A8-4A97-B3D5-7966A598C52AQ35063122-C2FFA181-D000-4BDC-B365-F09C05C8B2D2Q35393206-F3497FE6-0956-4897-8D27-2D3C9D63DD6DQ35551964-A5ED3BC2-63C8-4C09-BD98-715A61842260Q35568686-E6ACBB63-4BF1-44ED-A9F7-EF0D6DF1BE62Q35572096-2E5AB2F4-810A-4FE4-ADE9-E6C36CBC0BCCQ35587729-D35B560C-7268-4ED6-9BBB-0CA22B3874CAQ35749637-1AFF9B93-BFCE-44F2-8667-19444F61049AQ35764713-974C582A-B991-45DE-AD7D-C5FDF41E0F89Q35778045-B054BF3D-DDC1-4FB4-9044-65BE38D1E653Q35815625-032B2DAA-9FFE-4D22-A3ED-C1A1F3F3E18EQ35840288-605D2972-ABC4-4C01-ADE1-20B84809576BQ35963203-84D58C89-CBA6-4922-B487-F158B80FA93DQ36312897-4FD92785-63B7-4CAB-A5F4-EC912DC0ACF1
P2860
Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Intracellular protein degradat ...... n diseases and drug targeting.
@ast
Intracellular protein degradat ...... n diseases and drug targeting.
@en
type
label
Intracellular protein degradat ...... n diseases and drug targeting.
@ast
Intracellular protein degradat ...... n diseases and drug targeting.
@en
prefLabel
Intracellular protein degradat ...... n diseases and drug targeting.
@ast
Intracellular protein degradat ...... n diseases and drug targeting.
@en
P2860
P356
P1476
Intracellular protein degradat ...... n diseases and drug targeting.
@en
P2860
P2888
P304
P356
10.1038/SJ.CDD.4401692
P577
2005-09-01T00:00:00Z